Highlights of the Day III Genitourinary (Nonprostate) Cancer Presented By Toni Choueiri at 2014 ASCO Annual Meeting.

Slides:

Advertisements

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Advertisements

ASCO G.U Lawrence H. Einhorn.

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Highlights of the Day II: SARCOMA “The not so Old and the New” Presented By Dennis Priebat at 2014 ASCO Annual Meeting.

Slide 1 Presented By Mark Stein at 2014 ASCO Annual Meeting.

The 70-Gene Profile and Chemotherapy Benefit in 1,600 Breast Cancer Patients Bender RA et al. ASCO 2009; Abstract 512. (Oral Presentation)

Randomized Trial of p53 Targeted Adjuvant Therapy for Patients (pts) With Organ-Confined Node-Negative Urothelial Bladder Cancer.

Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.

Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.

Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.

Randomized Comparison of Adjuvant Aromatase Inhibitor Exemestane plus Ovarian Function Suppression vs Tamoxifen plus Ovarian Function Suppression in Premenopausal.

Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.

Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS , ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.

Slide 1 Presented By Edward Neuwelt at 2014 ASCO Annual Meeting.

Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Highlights of the Day-Plenary Session June 1, 2014 Lowell E. Schnipper, M.D. Presented By Lowell Schnipper at 2014 ASCO Annual Meeting.

Slide 1 Presented By Pierre-Yves Dietrich at 2014 ASCO Annual Meeting.

Immediate vs. deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study Presented.

HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.

Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.

May 29 - June 2, 2015 Atezolizumab (MPDL3280A) Shows Favorable Tolerability, Promising Activity in Urothelial Bladder Cancer CCO Independent Conference.

Return to Home! Go To Next Slide! Return to Home! Go To Next Slide!

MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.

A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (Moga) vs Investigator’s Choice (IC) in the Treatment of Patients.

Risk Stratification in Stage II Colon Cancer Patients Ramzi Amri, MD, PhD; Liliana G Bordeianou, MD, MPH; and David L Berger, MD Massachusetts General.

POPLAR: Atezolizumab Improved Survival vs Docetaxel in Patients With Advanced NSCLC and Increasing Levels of PD-L1 Expression CCO Independent Conference.

Dr. Marco Matos JOURNAL CLUB GCUH 4/07/14.

Ο ρόλος των μη χειρουργικών θεραπειών στο μη μεταστατικό μυοδιηθητικό καρκίνο ουροδόχου κύστεως Γεώργιος Δ. Λύπας Παθολόγος Ογκολόγος Α’ Ογκολογική Κλινική.

Presented By Shin Fujita at 2016 ASCO Annual Meeting

R3 이운주/Prof 맹치훈. Introduction Pancreatic adenocarcinoma is most lethal cancer, with a 5-year survival rate of less than 5%. Relapsed occurs in 80-85%

Presented By Alan Venook at 2016 ASCO Annual Meeting

May 29 - June 2, 2015 KEYNOTE-028: Antitumor Activity With Pembrolizumab in Patients With PD-L1- Positive Extensive-Stage SCLC CCO Independent Conference.

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 KRISTINE: Neoadjuvant T-DM1 + Pertuzumab vs Chemotherapy With Trastuzumab.

Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC

KEYNOTE-045: Updated Survival Analysis of Phase III Trial of Pembrolizumab vs Paclitaxel, Docetaxel, or Vinflunine in Pts With Advanced Urothelial Carcinoma.

CCO Independent Conference Highlights

Presented By Lorenz Trumper at 2016 ASCO Annual Meeting

CCO Independent Conference Coverage

CCO Independent Conference Highlights

CCO Independent Conference Coverage

Securing the cure in resectable lung cancer

Highlights: Myeloma Oral Session

Presented By Antoni Ribas at 2014 ASCO Annual Meeting

Colorectal Cancer Update Patient Perspectives on Colorectal Cancer

continued on next slide

Presented By Amrita Krishnan at 2016 ASCO Annual Meeting

TPOAb and Thyroid Function Are Not Associated with Breast Cancer Outcome: Evidence from a Large-Scale Study Using Data from the Taxotere as Adjuvant Chemotherapy.

continued on next slide

continued on next slide

Presented By James Rubenstein at 2016 ASCO Annual Meeting

Updates on the Use of Adjuvant Therapy in HER2-Positive Breast Cancer

ФОНД ЗА РАЗВОЈ РЕПУБЛИКЕ СРБИЈЕ

Metastatic Renal Cell Carcinoma

Volume 73, Issue 2, Pages (February 2018)

Presented By Johanna Bendell at 2016 ASCO Annual Meeting

Advancing Care in Genitourinary Cancer: Perspectives From Chicago

Presented By Mathias Rummel at 2016 ASCO Annual Meeting

'III \-\- I ', I ,, - -

Background: Gene Expression

continued on next slide

Presented By Joshua Richter at 2016 ASCO Annual Meeting

Presented By Andrew Evens at 2016 ASCO Annual Meeting

Abstract or Presentation Title Presenters Name Presenters Institution

continued on next slide

Presentation transcript:

Highlights of the Day III Genitourinary (Nonprostate) Cancer Presented By Toni Choueiri at 2014 ASCO Annual Meeting

Disclosures Presented By Toni Choueiri at 2014 ASCO Annual Meeting

Learning Objectives Presented By Toni Choueiri at 2014 ASCO Annual Meeting

Slide 4 Presented By Toni Choueiri at 2014 ASCO Annual Meeting

Updated 2013 meta-analysis of adjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer Presented By Toni Choueiri at 2014 ASCO Annual Meeting

Slide 6 Presented By Toni Choueiri at 2014 ASCO Annual Meeting

MPDL3280A: Summary of Response in UBC Investigator Assessed Presented By Toni Choueiri at 2014 ASCO Annual Meeting

Slide 8 Presented By Toni Choueiri at 2014 ASCO Annual Meeting

PD-L1 (+) tumor by IHC in RCC and outcome Presented By Toni Choueiri at 2014 ASCO Annual Meeting

Slide 10 Presented By Toni Choueiri at 2014 ASCO Annual Meeting

Slide 11 Presented By Toni Choueiri at 2014 ASCO Annual Meeting

Slide 12 Presented By Toni Choueiri at 2014 ASCO Annual Meeting

Slide 13 Presented By Toni Choueiri at 2014 ASCO Annual Meeting

Slide 14 Presented By Toni Choueiri at 2014 ASCO Annual Meeting

Slide 15 Presented By Toni Choueiri at 2014 ASCO Annual Meeting

Slide 16 Presented By Toni Choueiri at 2014 ASCO Annual Meeting

Slide 17 Presented By Toni Choueiri at 2014 ASCO Annual Meeting

Take Home messages Presented By Toni Choueiri at 2014 ASCO Annual Meeting

Slide 19 Presented By Toni Choueiri at 2014 ASCO Annual Meeting